[2]
Pusztai, L.; Karn, T.; Safonov, A.; Abu-Khalaf, M.M.; Bianchini, G. New strategies in breast cancer: immunotherapy. Clin. Cancer Res., 2016, 22(9), 2105-2110.
[17]
Leal, H.S.H.M. Breast cancer immunotherapy: from biology to current clinical applications. Eur. Med. J., 2020, 5(2), 113-124.
[19]
Adams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; Iwata, H.; Campone, M.; Nanda, R.; Hui, R.; Curigliano, G.; Toppmeyer, D.; O’Shaughnessy, J.; Loi, S.; Paluch-Shimon, S.; Tan, A.R.; Card, D.; Zhao, J.; Karantza, V.; Cortes, J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann. Oncol., 2019, 30(3), 397-404.
[26]
Dent, R.; Andre, F.; Goncalves, A.; Kummel, S.; Martin, M.; Schmid, P.; Schuetz, F.; Swain, S.M.; Easton, V.; Pollex, E.; Cortés, J. 2018.
[33]
Szekely, B.; Bossuyt, V.; Li, X.; Wali, V.B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V.; Zhang, M.; Yan, Q.; Rimm, D.L.; Bianchini, G.; Hatzis, C.; Pusztai, L. Immunological differences between primary and metastatic breast cancer. Ann. Oncol., 2018, 29(11), 2232-2239.
[36]
Gianni, L.; Huang, C-S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Bianchini, G.; Russo, S.; Ciruelos, E.; Greil, R.; Semiglazov, V.; Colleoni, M.; Kelly, C.; Mariani, G.; Mastro, L.D.; Maffeis, I.; Valagussa, P.; Viale, G. Abstract GS3-04: Pathologic Complete Response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res., 2020, 80(4)(Suppl.), GS3-GS04.
[38]
Rugo, H.S.; Delord, J.P. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin. Cancer Res., 2018, 24(12), 2804-2811.
[39]
Tolaney, S.M.; Barroso-Sousa, R.; Keenan, T.; Trippa, L.; Hu, J.; Luis, I.M.V.D.; Wulf, G.M.; Spring, L.; Sinclair, N.F.; Andrews, C.; Pittenger, J.D.; Richardson, E.T.; Dillon, D.; Lin, N.U.; Overmoyer, B.; Partridge, A.H.; VanAllen, E.; Mittendorf, E.A.; Winer, E.P.; Krop, I.E. Randomized phase II study of Eribulin mesylate (E) with or without Pembrolizumab (P) for Hormone Receptor-positive (HR plus) Metastatic Breast Cancer (MBC). J. Clin. Oncol., 2019, 37(15), 1004.
[41]
Rugo, H.S.; Kabos, P.; Beck, J.T.; Chisamore, M.J.; Hossain, A.; Chen, Y.; Tolaney, S.M. 2020.
[48]
Smith, W.M.; Purvis, I.J.; Bomstad, C.N.; Labak, C.M.; Velpula, K.K.; Tsung, A.J.; Regan, J.N.; Venkataraman, S.; Vibhakar, R.; Asuthkar, S. Therapeutic targeting of immune checkpoints with small molecule inhibitors. Am. J. Transl. Res., 2019, 11(2), 529-541.
[56]
Curigliano, G.; Burstein, H.J.; Winer, E.P.; Gnant, M.; Dubsky, P.; Loibl, S.; Colleoni, M.; Regan, M.M.; Piccart-Gebhart, M.; Senn, H.J.; Thürlimann, B.; André, F.; Baselga, J.; Bergh, J.; Bonnefoi, H.; Brucker, S.Y.; Cardoso, F.; Carey, L.; Ciruelos, E.; Cuzick, J.; Denkert, C.; Di Leo, A.; Ejlertsen, B.; Francis, P.; Galimberti, V.; Garber, J.; Gulluoglu, B.; Goodwin, P.; Harbeck, N.; Hayes, D.F.; Huang, C.S.; Huober, J.; Hussein, K.; Jassem, J.; Jiang, Z.; Karlsson, P.; Morrow, M.; Orecchia, R.; Osborne, K.C.; Pagani, O.; Partridge, A.H.; Pritchard, K.; Ro, J.; Rutgers, E.J.T.; Sedlmayer, F.; Semiglazov, V.; Shao, Z.; Smith, I.; Toi, M.; Tutt, A.; Viale, G.; Watanabe, T.; Whelan, T.J.; Xu, B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Ann. Oncol., 2017,
28(8), 1700-1712.
[
http://dx.doi.org/10.1093/annonc/mdx308]
[65]
Denkert, C.; Wienert, S.; Poterie, A.; Loibl, S.; Budczies, J.; Badve, S.; Bago-Horvath, Z.; Bane, A.; Bedri, S.; Brock, J.; Chmielik, E.; Christgen, M.; Colpaert, C.; Demaria, S.; Van den Eynden, G.; Floris, G.; Fox, S.B.; Gao, D.; Ingold Heppner, B.; Kim, S.R.; Kos, Z.; Kreipe, H.H.; Lakhani, S.R.; Penault-Llorca, F.; Pruneri, G.; Radosevic-Robin, N.; Rimm, D.L.; Schnitt, S.J.; Sinn, B.V.; Sinn, P.; Sirtaine, N.; O’Toole, S.A.; Viale, G.; Van de Vijver, K.; de Wind, R.; von Minckwitz, G.; Klauschen, F.; Untch, M.; Fasching, P.A.; Reimer, T.; Willard-Gallo, K.; Michiels, S.; Loi, S.; Salgado, R. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Mod. Pathol., 2016,
29(10), 1155-1164.
[
http://dx.doi.org/10.1038/modpathol.2016.109]
[81]
Han, Y.; Liu, D.; Li, L. PD-1/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res., 2020, 10(3), 727-742.
[98]
Fusco, N.; Lopez, G.; Corti, C.; Pesenti, C.; Colapietro, P.; Ercoli, G.; Gaudioso, G.; Faversani, A.; Gambini, D.; Michelotti, A.; Despini, L.; Blundo, C.; Vaira, V.; Miozzo, M.; Ferrero, S.; Bosari, S. 2018.
[100]
Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; Wong, F.; Azad, N.S.; Rucki, A.A.; Laheru, D.; Donehower, R.; Zaheer, A.; Fisher, G.A.; Crocenzi, T.S.; Lee, J.J.; Greten, T.F.; Duffy, A.G.; Ciombor, K.K.; Eyring, A.D.; Lam, B.H.; Joe, A.; Kang, S.P.; Holdhoff, M.; Danilova, L.; Cope, L.; Meyer, C.; Zhou, S.; Goldberg, R.M.; Armstrong, D.K.; Bever, K.M.; Fader, A.N.; Taube, J.; Housseau, F.; Spetzler, D.; Xiao, N.; Pardoll, D.M.; Papadopoulos, N.; Kinzler, K.W.; Eshleman, J.R.; Vogelstein, B.; Anders, R.A.; Diaz, L.A., Jr Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science, 2017,
357(6349), 409-413.
[
http://dx.doi.org/10.1126/science.aan6733]
[103]
Zehir, A.; Benayed, R.; Shah, R.H.; Syed, A.; Middha, S.; Kim, H.R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S.M.; Hellmann, M.D.; Barron, D.A.; Schram, A.M.; Hameed, M.; Dogan, S.; Ross, D.S.; Hechtman, J.F.; DeLair, D.F.; Yao, J.; Mandelker, D.L.; Cheng, D.T.; Chandramohan, R.; Mohanty, A.S.; Ptashkin, R.N.; Jayakumaran, G.; Prasad, M.; Syed, M.H.; Rema, A.B.; Liu, Z.Y.; Nafa, K.; Borsu, L.; Sadowska, J.; Casanova, J.; Bacares, R.; Kiecka, I.J.; Razumova, A.; Son, J.B.; Stewart, L.; Baldi, T.; Mullaney, K.A.; Al-Ahmadie, H.; Vakiani, E.; Abeshouse, A.A.; Penson, A.V.; Jonsson, P.; Camacho, N.; Chang, M.T.; Won, H.H.; Gross, B.E.; Kundra, R.; Heins, Z.J.; Chen, H.W.; Phillips, S.; Zhang, H.; Wang, J.; Ochoa, A.; Wills, J.; Eubank, M.; Thomas, S.B.; Gardos, S.M.; Reales, D.N.; Galle, J.; Durany, R.; Cambria, R.; Abida, W.; Cercek, A.; Feldman, D.R.; Gounder, M.M.; Hakimi, A.A.; Harding, J.J.; Iyer, G.; Janjigian, Y.Y.; Jordan, E.J.; Kelly, C.M.; Lowery, M.A.; Morris, L.G.T.; Omuro, A.M.; Raj, N.; Razavi, P.; Shoushtari, A.N.; Shukla, N.; Soumerai, T.E.; Varghese, A.M.; Yaeger, R.; Coleman, J.; Bochner, B.; Riely, G.J.; Saltz, L.B.; Scher, H.I.; Sabbatini, P.J.; Robson, M.E.; Klimstra, D.S.; Taylor, B.S.; Baselga, J.; Schultz, N.; Hyman, D.M.; Arcila, M.E.; Solit, D.B.; Ladanyi, M.; Berger, M.F. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nat. Med., 2017,
23(6), 703-713.
[
http://dx.doi.org/10.1038/nm.4333]
[108]
Lawrence, M.S.; Stojanov, P.; Polak, P.; Kryukov, G.V.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.; Stewart, C.; Mermel, C.H.; Roberts, S.A.; Kiezun, A.; Hammerman, P.S.; McKenna, A.; Drier, Y.; Zou, L.; Ramos, A.H.; Pugh, T.J.; Stransky, N.; Helman, E.; Kim, J.; Sougnez, C.; Ambrogio, L.; Nickerson, E.; Shefler, E.; Cortés, M.L.; Auclair, D.; Saksena, G.; Voet, D.; Noble, M.; DiCara, D.; Lin, P.; Lichtenstein, L.; Heiman, D.I.; Fennell, T.; Imielinski, M.; Hernandez, B.; Hodis, E.; Baca, S.; Dulak, A.M.; Lohr, J.; Landau, D.A.; Wu, C.J.; Melendez-Zajgla, J.; Hidalgo-Miranda, A.; Koren, A.; McCarroll, S.A.; Mora, J.; Crompton, B.; Onofrio, R.; Parkin, M.; Winckler, W.; Ardlie, K.; Gabriel, S.B.; Roberts, C.W.M.; Biegel, J.A.; Stegmaier, K.; Bass, A.J.; Garraway, L.A.; Meyerson, M.; Golub, T.R.; Gordenin, D.A.; Sunyaev, S.; Lander, E.S.; Getz, G. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Nature, 2013,
499(7457), 214-218.
[
http://dx.doi.org/10.1038/nature12213]
[113]
Huang, R.S.P.; Haberberger, J.; Severson, E.; Duncan, D.L.; Hemmerich, A.; Edgerly, C.; Ferguson, N.L.; Williams, E.; Elvin, J.; Vergilio, J.A.; Killian, J.K.; Lin, D.I.; Tse, J.; Hiemenz, M.; Owens, C.; Danziger, N.; Hegde, P.S.; Venstrom, J.; Alexander, B.; Ross, J.S.; Ramkissoon, S.H. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod. Pathol., 2021, 34(2), 252-263.
[117]
Lan, H.; Bu, Q.; Zhuang, L.; Ren, S.; Yan, X.; Li, Y.; Yu, Q.; Shi, X.; Zhao, J.; Guo, H.; Zhao, L. Frequency of homologous recombination-related gene mutations in breast cancer and their correlation with tumor mutation burden., 2020.
[124]
Legrand, F.A.; Gandara, D.R.; Mariathasan, S.; Powles, T.; He, X.; Zhang, W.; Jhunjhunwala, S.; Nickles, D.; Bourgon, R.; Schleifman, E.; Paul, S.M.; Kadel, E.E.; Kowanetz, M.; Cummings, C.; Li, Y.; Fabrizio, D.; Peters, E.; Hegde, P.S.; Amler, L.; Shames, D.S. Association of high tissue TMB and atezolizumab efficacy across multiple tumor types., 2018.
[126]
Samstein, R.M.; Lee, C.H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.; Jordan, E.J.; Omuro, A.; Kaley, T.J.; Kendall, S.M.; Motzer, R.J.; Hakimi, A.A.; Voss, M.H.; Russo, P.; Rosenberg, J.; Iyer, G.; Bochner, B.H.; Bajorin, D.F.; Al-Ahmadie, H.A.; Chaft, J.E.; Rudin, C.M.; Riely, G.J.; Baxi, S.; Ho, A.L.; Wong, R.J.; Pfister, D.G.; Wolchok, J.D.; Barker, C.A.; Gutin, P.H.; Brennan, C.W.; Tabar, V.; Mellinghoff, I.K.; DeAngelis, L.M.; Ariyan, C.E.; Lee, N.; Tap, W.D.; Gounder, M.M.; D’Angelo, S.P.; Saltz, L.; Stadler, Z.K.; Scher, H.I.; Baselga, J.; Razavi, P.; Klebanoff, C.A.; Yaeger, R.; Segal, N.H.; Ku, G.Y.; DeMatteo, R.P.; Ladanyi, M.; Rizvi, N.A.; Berger, M.F.; Riaz, N.; Solit, D.B.; Chan, T.A.; Morris, L.G.T. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nat. Genet., 2019,
51(2), 202-206.
[
http://dx.doi.org/10.1038/s41588-018-0312-8]
[134]
Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M.S.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.S.; Biganzoli, L.; Boyle, F.; Cardoso, M.J.; Carey, L.A.; Cortés, J.; El Saghir, N.S.; Elzayat, M.; Eniu, A.; Fallowfield, L.; Francis, P.A.; Gelmon, K.; Gligorov, J.; Haidinger, R.; Harbeck, N.; Hu, X.; Kaufman, B.; Kaur, R.; Kiely, B.E.; Kim, S.B.; Lin, N.U.; Mertz, S.A.; Neciosup, S.; Offersen, B.V.; Ohno, S.; Pagani, O.; Prat, A.; Penault-Llorca, F.; Rugo, H.S.; Sledge, G.W.; Thomssen, C.; Vorobiof, D.A.; Wiseman, T.; Xu, B.; Norton, L.; Costa, A.; Winer, E.P. 5
th ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 5).
Ann. Oncol., 2020,
31(12), 1623-1649.
[
http://dx.doi.org/10.1016/j.annonc.2020.09.010]
[154]
Hong, D.S.; Schoffski, P.; Calvo, A.; Sarantopoulos, J.; Ochoa De Olza, M.; Carvajal, R.D.; Prawira, A.; Kyi, C.; Esaki, T.; Akerley, W.L.; De Braud, F.G.; Hui, R.; Zhang, T.; Soo, R.A.; Maur, M.; Weickhardt, A.J.; Roy Chowdhury, N.; Sabatos-Peyton, C.; Kwak, E.L.; Tan, D.S.-W. 2018.
